Double Biologic Therapy for Refractory Stricturing Crohn's Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab

Ahmed Elmoursi; Terrence A. Barrett; Courtney Perry

doi:10.1093/ibd/izaa092

Double Biologic Therapy for Refractory Stricturing Crohn's Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab

Research output: Contribution to journal › Letter › peer-review

25 Scopus citations

Original language	English
Pages (from-to)	e62-e63
Journal	Inflammatory Bowel Diseases
Volume	26
Issue number	7
DOIs	https://doi.org/10.1093/ibd/izaa092
State	Published - Jun 18 2020

Bibliographical note

Funding Information:
From the Division of Gastroenterology, Department of Internal Medicine, University of Kentucky, USA Supported by: CP is supported by the National Institutes of Health, Grant TL1TR001997 of CCTS funding. The authors’ work is also supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R21DK118954. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was supported in part by Merit Review Award #I01CX001353 to TAB from the United States Department of Veterans Affairs Laboratory Research and Development Program.

Funding

From the Division of Gastroenterology, Department of Internal Medicine, University of Kentucky, USA Supported by: CP is supported by the National Institutes of Health, Grant TL1TR001997 of CCTS funding. The authors’ work is also supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R21DK118954. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was supported in part by Merit Review Award #I01CX001353 to TAB from the United States Department of Veterans Affairs Laboratory Research and Development Program.

Funders	Funder number
Department of Internal Medicine, University of Kentucky
United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases	01CX001353, R21DK118954
National Institute of Diabetes and Digestive and Kidney Diseases
National Center for Advancing Translational Sciences (NCATS)	TL1TR001997
National Center for Advancing Translational Sciences (NCATS)
Center for Clinical and Translational Science, University of Utah

Keywords

Crohn's disease
double biologic therapy (DBT)
stricture
ustekinumab
vedolizumab

ASJC Scopus subject areas

Immunology and Allergy
Gastroenterology

Access to Document

10.1093/ibd/izaa092

Cite this

@article{06c66e9c2da44d20b7db198933f773a9,

title = "Double Biologic Therapy for Refractory Stricturing Crohn's Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab",

keywords = "Crohn's disease, double biologic therapy (DBT), stricture, ustekinumab, vedolizumab",

author = "Ahmed Elmoursi and Barrett, \{Terrence A.\} and Courtney Perry",

note = "Funding Information: From the Division of Gastroenterology, Department of Internal Medicine, University of Kentucky, USA Supported by: CP is supported by the National Institutes of Health, Grant TL1TR001997 of CCTS funding. The authors{\textquoteright} work is also supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R21DK118954. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was supported in part by Merit Review Award \#I01CX001353 to TAB from the United States Department of Veterans Affairs Laboratory Research and Development Program.",

year = "2020",

month = jun,

day = "18",

doi = "10.1093/ibd/izaa092",

language = "English",

volume = "26",

pages = "e62--e63",

number = "7",

}

TY - JOUR

T1 - Double Biologic Therapy for Refractory Stricturing Crohn's Disease

T2 - A Successful Case of Deep Remission with Ustekinumab and Vedolizumab

AU - Elmoursi, Ahmed

AU - Barrett, Terrence A.

AU - Perry, Courtney

N1 - Funding Information: From the Division of Gastroenterology, Department of Internal Medicine, University of Kentucky, USA Supported by: CP is supported by the National Institutes of Health, Grant TL1TR001997 of CCTS funding. The authors’ work is also supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R21DK118954. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was supported in part by Merit Review Award #I01CX001353 to TAB from the United States Department of Veterans Affairs Laboratory Research and Development Program.

PY - 2020/6/18

Y1 - 2020/6/18

KW - Crohn's disease

KW - double biologic therapy (DBT)

KW - stricture

KW - ustekinumab

KW - vedolizumab

UR - https://www.scopus.com/pages/publications/85086749865

UR - https://www.scopus.com/pages/publications/85086749865#tab=citedBy

U2 - 10.1093/ibd/izaa092

DO - 10.1093/ibd/izaa092

M3 - Letter

C2 - 32386054

AN - SCOPUS:85086749865

SN - 1078-0998

VL - 26

SP - e62-e63

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

IS - 7

ER -

Double Biologic Therapy for Refractory Stricturing Crohn's Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this